Drag a card by its title · ⚙ to size, swap or remove

The company

Crescent Biopharma, Inc.

CBIO · Nasdaq

Health CareBiotechnologyNot moving yet

CBIO stood above a rising 150-day average in 21 of the last 52 weekly readings, and has been out of that trend for the last 5 weeks. It is 31.6% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

SEC filings

Statistics

Rotation: Not moving yet
Weeks in an uptrend: out for 5
Industry in uptrend: 15% -17 in 4 wk
Insider buys, 12 months: $43.0M
Insider sales, 12 months: $3.0M
Officials’ trades on record: 0
Institutions holding: 82 (+22)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 21 of 52 weeks.

17 Apr – 16 Oct

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months3

Sale orders, 12 months16

Buyers · sellers3 · 7

Who	Did	Shares	Traded
Jonathan McNeillPresident and COO	sold	3,839at $16.71	18 Sep 2026filed 18 Sep 2026
Joshua T. BrummChief Executive Officer	sold	7,837at $16.71	18 Sep 2026filed 18 Sep 2026
Jonathan McNeillPresident and COO	sold	731at $17.90	16 Sep 2026filed 18 Sep 2026
Joshua T. BrummChief Executive Officer	sold	1,610at $17.90	16 Sep 2026filed 18 Sep 2026
Barbara Harlin BisphamOfficer	sold	620at $17.90	16 Sep 2026filed 18 Sep 2026
Richard William ScalzoChief Financial Officer	sold	568at $17.90	16 Sep 2026filed 18 Sep 2026
Ellie Eunkyung ImChief Medical Officer	sold	623at $17.90	16 Sep 2026filed 18 Sep 2026
Jan PinkasChief Scientific Officer	sold	658at $17.90	16 Sep 2026filed 18 Sep 2026
Ryan LynchOfficer	sold	240at $17.90	16 Sep 2026filed 18 Sep 2026
Fairmount Funds Management LlcDirector, 10% owner	bought	853,450at $14.50	16 Jul 2026filed 20 Jul 2026
Fairmount Funds Management LlcDirector, 10% owner	bought	525,897at $14.50	16 Jul 2026filed 20 Jul 2026
Joshua T. BrummChief Executive Officer	sold	42,305at $17.99	22 Jun 2026filed 23 Jun 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders82+22 on the quarter

New · exited33 · 11

Reported value$528.5M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

Manager	Shares	Change
FMR LLCunchanged · filed 13 Aug 2026	4,133,514$74.4M	00.0%
BVF INCunchanged · filed 14 Aug 2026	2,748,763$49.5M	00.0%
Fairmount Funds Management LLCunchanged · filed 14 Aug 2026	2,747,866$49.5M	00.0%
Venrock Adviser, LLCunchanged · filed 14 Aug 2026	2,133,576$38.4M	00.0%
Logos Global Management LPadded · filed 14 Aug 2026	1,900,000$34.2M	+1,417,500+293.8%
FCPM III SERVICES B.V.unchanged · filed 14 Aug 2026	1,677,852$30.2M	00.0%
Balyasny Asset Management L.P.added · filed 14 Aug 2026	1,662,917$29.9M	+152,884+10.1%
Vestal Point Capital, LPadded · filed 14 Aug 2026	1,630,000$29.3M	+130,000+8.7%
Opaleye Management Inc.added · filed 14 Aug 2026	1,319,351$23.7M	+6,736+0.5%
BlackRock, Inc.added · filed 7 Aug 2026	1,271,762$22.9M	+1,156,037+999.0%